EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Gregor A Maier iD, Ramon A Hofmann, Michael Roden iD, Wolfgang Rathmann iD, Oliver Kuss iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Gregor A Maier und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Ger…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear. This study compared the effectiveness of GLP‐1 RAs versus SGLT‐2 inhibitors on major adverse liver outcomes (MALO), liver cirrhosis and all‐cause mortality in people with MASLD and type 2 diabetes. Materials and Methods This active comparator, new‐user cohort study used claims data from Germany (2005–2024), including 45 256 people with MASLD and type 2 diabetes. New users of GLP‐1 RAs ( n = 9993) and SGLT‐2 inhibitors ( n = 35 263) were weighted using matching weights. The primary outcome was MALO, while secondary outcomes comprised individual MALO components (decompensation events, liver transplantation, hepatocellular carcinoma (HCC)), liver cirrhosis and all‐cause mortality. Hazard ratios (HR) with 95% confidence intervals (CI) were estimated with weighted Cox proportional hazard models.

Results

Over a median 4.3‐year follow‐up, new users of GLP‐1 RAs had a lower hazard of MALO (HR 0.91, 95% CI 0.78–1.07). This association appeared stronger using an on‐treatment approach (HR 0.78, 95% CI 0.58–1.03) and when restricting to hospital diagnoses in primary position (HR 0.77, 95% CI 0.56–1.07). Benefits were also observed for liver cirrhosis (HR 0.88), decompensation events (HR 0.91), HCC (HR 0.76), but not all‐cause mortality (HR 1.04).

Conclusions

GLP‐1 RAs were associated with a potentially lower hazard for incident MALO and liver cirrhosis compared with SGLT‐2 inhibitors in people with MASLD and type 2 diabetes, suggesting a possible therapeutic advantage for liver‐specific outcomes in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsNon-alcoholic Fatty Liver DiseaseFatty LiverHumansFemaleMaleMiddle AgedAgedLiver CirrhosisGermanyCohort StudiesIncidenceAdult

Stichwörter der Autor:innen

antidiabetic drugeffectivenessfatty liver diseaseobservational studypharmaco‐epidemiology

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany.
  • German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany.
  • Division of Endocrinology and Diabetology, Medical Faculty and University Hospital, Heinrich Heine University, University Hospital, Düsseldorf, Germany.
  • Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany.
  • Centre for Health and Society, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.

ORCID-Profile: Gregor A Maier, Michael Roden, Wolfgang Rathmann, Oliver Kuss

Zitieren

APA

Maier, G. A., Hofmann, R. A., Roden, M., Rathmann, W., & Kuss, O. (2026). Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71023

Vancouver

Maier GA, Hofmann RA, Roden M, Rathmann W, Kuss O. Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71023

BibTeX
@article{Maier2026,
  author = {Maier, Gregor A and Hofmann, Ramon A and Roden, Michael and Rathmann, Wolfgang and Kuss, Oliver},
  title = {Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71023}
}
Kostenlos starten →